Kidney failure is a severe state of kidney disease in which kidney function falls below about 15% of normal. At this stage, patients typically require kidney replacement therapy such as hemodialysis, peritoneal dialysis, or kidney transplant.
FDA approved Novartis' Fabhalta for IgAN to slow kidney function decline. Phase III ALIGN data for Vanrafia showed ~34% slower eGFR decline vs placebo and were published in The Lancet.
FDA granted traditional approval to Novartis' Fabhalta (iptacopan) for IgA nephropathy. Phase 3 APPLAUSE-IgAN data showed eGFR decline slowed by 48% versus placebo over two years.
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
New research demonstrates machine learning can optimize drug dosing, identifies biomarkers of treatment response, and validates prognostic criteria for long-term kidney survival in pediatric lupus nephritis patients.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
Phase 3 trials demonstrate atrasentan slows kidney function decline in IgA nephropathy patients, while obinutuzumab achieves superior remission rates in primary membranous nephropathy compared to standard treatment.
Scientists in China report reversing Type 2 diabetes in a patient using stem cell therapy, while a separate study finds metformin may help women with diabetes live past 90. Both findings require larger trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07765134 |
Comprehensive Kidney Function Assessment and Early Warning in Older Adults |
COMPLETED | |
| NCT07765030 |
Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department |
NOT_YET_RECRUITING | |
| NCT07754331 |
Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin |
NOT_YET_RECRUITING | PHASE1 |
| NCT07704008 |
The Effect of Virtual Reality Glasses Applied to Hemodialysis Patients on Vital Signs and Anxiety Level |
COMPLETED | NA |
| NCT07606183 |
Effects of Different Forms of a Natural Heart Hormone on Blood Pressure and Fluid Balance in Healthy Volunteers |
COMPLETED | EARLY_PHASE1 |
| NCT07492511 |
Renal and Hepatic Abnormal Doppler Patterns in Trauma |
RECRUITING | |
| NCT07484308 |
Application and Impact Assessment of Ultrasound Super-Resolution Blood Flow Imaging (URM) in Patients With Renal Failure |
COMPLETED | NA |
| NCT07446296 |
Kidney Transplant Improvement Through New Exercise Training to Increase Capacity |
RECRUITING | NA |
| NCT07419945 |
Older Kidney Patient Optimisation Pretransplant |
NOT_YET_RECRUITING | NA |
| NCT07377500 |
Dialysate Cooling for the Preservation of Cognitive Function in People Receiving Haemodialysis |
NOT_YET_RECRUITING | NA |
